Coherus Biosciences (CHRS) PT Lowered to $8 at Barclays
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.20 +5.26%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Coherus Biosciences (NASDAQ: CHRS) to $8.00 (from $13.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities
- GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
